Medical technology company Memphasys plans its first commercial sales of its unique Felix medical device to boost success in IVF procedures in the second half of 2020.
The Sydney company told investors in a market update that its automated, non-DNA damaging lab instrument for sperm separation was undergoing assessment by a series of key opinion leaders in the IVF industry.
Male infertility is a big factor in failure of IVF treatments, with sperm quality rather than quantity the key issue.
The Felix device (pictured below) uses an electric force and polymer membranes to separate sperm, selecting the best quality, negatively charged sperm for use in the IVF process.
The key opinion leaders have been selected for their expertise and geographic spread, and influence in the commercialisation of the Felix device.
Felix is based on Memphasys’s CS10 lab instrument developed 10 years ago using the company’s ‘porous Membrane + electrophoresis’ platform technology for separation of cells and molecules.
Memphasys worked with Prof John Aitken and his associates at the University of Newcastle to develop the instrument to gently separate sperm from semen samples.
The company aims to develop Feliz as the gold standard method in human IVF clinics for preparing sperm, and is also developing the technology for use in various artificial reproductive techniques (ART) for animals.
Subscribe to our free @AuManufacturing newsletter here.